ArticleScientific reports2015
Depth-resolved rhodopsin molecular contrast imaging for functional assessment of photoreceptors.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS.Retina (Philadelphia, Pa.) · 2020Trial
- Insights on Acute and Chronic Lacquer Cracks as Imaged with Visible Light OCT.Ophthalmology science · 2026Article
- Visible Light Optical Coherence Tomography: Technology and Biomedical Applications.Bioengineering (Basel, Switzerland) · 2025Review
- High-resolution visible light OCT of the human retina with combined superluminescent diodes.Optics letters · 2025Article
- Visible-light optical coherence tomography and its applications.Neurophotonics · 2025Review
- The Perspective of Using Optical Coherence Tomography in Ophthalmology: Present and Future Applications.Diagnostics (Basel, Switzerland) · 2025Review
- Emerging imaging developments in experimental vision sciences and ophthalmology.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Biomedical optical imaging technology and applications: From basic research toward clinical diagnosis.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- Improving visible light OCT of the human retina with rapid spectral shaping and axial tracking.Biomedical optics express · 2019Article
- Visible-light optical coherence tomography: a review.Journal of biomedical optics · 2017Review
- Automated Internal Classification of Beadless Chinese ZhuJi Freshwater Pearls based on Optical Coherence Tomography Images.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Rhodopsin, the light-sensing molecule in the outer segments of rod photoreceptors, is responsible for converting light into neuronal signals in a process known as phototransduction. Rhodopsin is thus a functional biomarker for rod photoreceptors. Here we report a novel technology based on visible-light optical coherence tomography (VIS-OCT) for in vivo molecular imaging of rhodopsin. The depth resolution of OCT allows the visualization of the location where the change of optical absorption occurs and provides a potentially accurate assessment of rhodopsin content by segmentation of the image at the location. Rhodopsin OCT can be used to quantitatively image rhodopsin distribution and thus assess the distribution of functional rod photoreceptors in the retina. Rhodopsin OCT can bring significant impact into ophthalmic clinics by providing a tool for the diagnosis and severity assessment of a variety of retinal conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.